Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31351862)

  • 1. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Floudas CS; Brar G; Mabry-Hrones D; Duffy AG; Wood B; Levy E; Krishnasamy V; Fioravanti S; Bonilla CM; Walker M; Morelli MP; Kleiner DE; Steinberg SM; Figg WD; Greten TF; Xie C
    Clin Colorectal Cancer; 2019 Dec; 18(4):e349-e360. PubMed ID: 31351862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
    Luke JJ; Lemons JM; Karrison TG; Pitroda SP; Melotek JM; Zha Y; Al-Hallaq HA; Arina A; Khodarev NN; Janisch L; Chang P; Patel JD; Fleming GF; Moroney J; Sharma MR; White JR; Ratain MJ; Gajewski TF; Weichselbaum RR; Chmura SJ
    J Clin Oncol; 2018 Jun; 36(16):1611-1618. PubMed ID: 29437535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
    Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
    Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
    Laheru D; Lutz E; Burke J; Biedrzycki B; Solt S; Onners B; Tartakovsky I; Nemunaitis J; Le D; Sugar E; Hege K; Jaffee E
    Clin Cancer Res; 2008 Mar; 14(5):1455-63. PubMed ID: 18316569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
    Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
    Zheng L; Edil BH; Soares KC; El-Shami K; Uram JN; Judkins C; Zhang Z; Onners B; Laheru D; Pardoll D; Jaffee EM; Schulick RD
    Ann Surg Oncol; 2014 Nov; 21(12):3931-7. PubMed ID: 24943235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
    Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
    Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
    McBride S; Sherman E; Tsai CJ; Baxi S; Aghalar J; Eng J; Zhi WI; McFarland D; Michel LS; Young R; Lefkowitz R; Spielsinger D; Zhang Z; Flynn J; Dunn L; Ho A; Riaz N; Pfister D; Lee N
    J Clin Oncol; 2021 Jan; 39(1):30-37. PubMed ID: 32822275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
    Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
    Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
    J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
    Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
    J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.
    Ahmed KA; Stallworth DG; Kim Y; Johnstone PA; Harrison LB; Caudell JJ; Yu HH; Etame AB; Weber JS; Gibney GT
    Ann Oncol; 2016 Mar; 27(3):434-41. PubMed ID: 26712903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.